Nature

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA ...
The American Journal of Managed Care

Commentary Shares Insights About Irradiated Blood to Prevent TA-GVHD

A new commentary outlines UK guidance about evidence regarding the appropriateness of blood component irradiation for preventing transfusion-associated graft-versus-host disease (TA-GVHD). Transfusion ...
The American Journal of Managed Care

Study Examines Treatment Link to Transplant Complication in GVHD

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD ...
Medscape

Allogeneic Blood Components

Patients with congenital or acquired cellular immunodeficiency are at risk of development of TA-GVHD, an almost universally fatal condition caused by seeding of donor lymphocytes in the ...
Nature

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a well-documented complication after allogeneic hematopoietic SCT (HSCT). 1 The reported incidence of TA-TMA varies greatly from ...